Abstract
BackgroundPrior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum samples collected in parallel from matched patients to determine whether urine IP-10 can be used to monitor treatment response in patients with active TB.MethodsIP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among healthy controls and patients at three time points, and LOESS regression was used for longitudinal data.ResultsThe levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a similar trend, but did not increase significantly after 2 months of treatment in patients with active TB.ConclusionsUnstimulated IP-10 in urine can be used as a biomarker to monitor treatment response in patients with active pulmonary TB.
Highlights
Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients
Bacille Calmette-Guérin (BCG) scars were present in 65.2% of patients with active TB and 57.1% of healthy controls during inspection at the site
Similar to the findings of Cannas et al [20], this study showed a declining tendency for urine inducible protein 10 (IP-10) detection in TB patients after receiving effective antiTB drug therapy compared the levels at time of diagnosis
Summary
Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. Prior to clinical trials of new therapeutic vaccines to prevent TB recurrence and to shorten the duration of therapy, effective monitoring tools are needed to measure treatment responses to standard drug therapies in parallel with therapeutic vaccinations [3, 4]. Sputum culture conversion after 2 months of anti-TB drug treatment has been used as a predictive indicator of drug treatment response in patients [5,6,7,8,9]. Culture methods are not applicable in patients with extrapulmonary TB and culture-negative
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
